{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:48:18Z","timestamp":1792511298408,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005601","name":"CLL Global Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008222","name":"The Ben and Catherine Ivy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of War","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103100","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:16:25Z","timestamp":1791558985000},"page":"103100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-integrated RNA therapeutics in precision oncology"],"prefix":"10.1016","volume":"7","author":[{"given":"William S.O.","family":"Symmans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-0578","authenticated-orcid":false,"given":"George A.","family":"Calin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103100_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41571-025-01114-x","article-title":"MicroRNAs in oncology: a translational perspective in the era of AI","volume":"23","author":"Jurj","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103100_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics\u2014challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib4","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","article-title":"RNA chemistry and therapeutics","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-025-02463-y","article-title":"Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications","volume":"24","author":"Yan","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.103100_bib6","article-title":"Clinical advances of mRNA vaccines for cancer immunotherapy","volume":"6","author":"Yaremenko","year":"2025","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.xcrm.2026.103100_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103100_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.tips.2022.01.008","article-title":"The potential of long noncoding RNA therapies","volume":"43","author":"Mercer","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.xcrm.2026.103100_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","article-title":"Circular RNA vaccine in disease prevention and treatment","volume":"8","author":"Niu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.xcrm.2026.103100_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: A bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103100_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad186","article-title":"Recent trends in RNA informatics: a review of machine learning and deep learning for RNA secondary structure prediction and RNA drug discovery","volume":"24","author":"Sato","year":"2023","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.xcrm.2026.103100_bib13","article-title":"Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy","volume":"14","author":"Imani","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.xcrm.2026.103100_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41746-023-00832-9","article-title":"Perspectives on validation of clinical predictive algorithms","volume":"6","author":"de Hond","year":"2023","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41576-019-0122-6","article-title":"Deep learning: new computational modelling techniques for genomics","volume":"20","author":"Eraslan","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.xcrm.2026.103100_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41576-025-00904-4","article-title":"Genomics of drug target prioritization for complex diseases","volume":"27","author":"Chen","year":"2026","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.xcrm.2026.103100_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1612474","article-title":"Artificial intelligence integrates multi-omics data for precision stratification and drug resistance prediction in breast cancer","volume":"15","author":"Ran","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2026.103100_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-024-01043-6","article-title":"Informing immunotherapy with multi-omics driven machine learning","volume":"7","author":"Li","year":"2024","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf440","article-title":"Deep learning\u2013driven multi-omics analysis: enhancing cancer diagnostics and therapeutics","volume":"26","author":"Zhang","year":"2025","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.xcrm.2026.103100_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae002","article-title":"Reliable method for predicting the binding affinity of RNA-small molecule interactions using machine learning","volume":"25","author":"Krishnan","year":"2024","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.xcrm.2026.103100_bib21","article-title":"Advances in RNA therapeutics: Classes, innovations and clinical applications","volume":"3","author":"Shahid","year":"2025","journal-title":"The Journal of Precision Medicine: Health and Disease"},{"key":"10.1016\/j.xcrm.2026.103100_bib22","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103100_bib23","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1038\/s41467-023-41303-9","article-title":"Integrating end-to-end learning with deep geometrical potentials for ab initio RNA structure prediction","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103100_bib24","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41592-024-02487-0","article-title":"Accurate RNA 3D structure prediction using a language model-based deep learning approach","volume":"21","author":"Shen","year":"2024","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.103100_bib25","article-title":"De Novo RNA Tertiary Structure Prediction at Atomic Resolution Using Geometric Potentials from Deep Learning","author":"Pearce","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2026.103100_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.1571","article-title":"RNA-ligand molecular docking: advances and challenges","volume":"12","author":"Zhou","year":"2022","journal-title":"WIREs Comput. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.103100_bib27","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1107\/S0907444902003451","article-title":"The Protein Data Bank","volume":"58","author":"Berman","year":"2002","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.xcrm.2026.103100_bib28","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1021\/acschembio.6b00001","article-title":"Inforna 2.0: a platform for the sequence-based design of small molecules targeting structured RNAs","volume":"11","author":"Disney","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.xcrm.2026.103100_bib29","article-title":"The prediction of RNA-small-molecule ligand binding using RNA-ligand surface interaction fingerprinting","volume":"41","author":"Xia","year":"2025","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.103100_bib30","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41573-022-00521-4","article-title":"Targeting RNA structures with small molecules","volume":"21","author":"Childs-Disney","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib31","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103100_bib32","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2019UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Castillo-Hair","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103100_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.103100_bib34","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","article-title":"Codon optimality is a major determinant of mRNA stability","volume":"160","author":"Presnyak","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103100_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.108015","article-title":"mRNA vaccine sequence and structure design and optimization: Advances and challenges","volume":"301","author":"Jin","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.103100_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.xcrm.2026.103100_bib38","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib39","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1016\/j.xphs.2024.09.015","article-title":"Review of machine learning for lipid nanoparticle formulation and process development","volume":"113","author":"Dorsey","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.xcrm.2026.103100_bib40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/pharmaceutics15020622","article-title":"mRNA-Based Therapeutics in Cancer Treatment","volume":"15","author":"Sun","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.103100_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103100_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adw0730","article-title":"Lipid nanoparticles for mRNA delivery in brain via systemic administration","volume":"11","author":"Cao","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.103100_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40580-025-00502-4","article-title":"Machine learning techniques for lipid nanoparticle formulation","volume":"12","author":"Li","year":"2025","journal-title":"Nano Converg."},{"key":"10.1016\/j.xcrm.2026.103100_bib44","article-title":"Lipid nanoparticle-mediated lymph node\u2013targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103100_bib45","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s42003-024-06235-0","article-title":"Overcoming thermostability challenges in mRNA\u2013lipid nanoparticle systems with piperidine-based ionizable lipids","volume":"7","author":"Hashiba","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.xcrm.2026.103100_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","article-title":"Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2","volume":"9","author":"Ai","year":"2023","journal-title":"Cell Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib47","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.apsb.2021.11.021","article-title":"Prediction of lipid nanoparticles for mRNA vaccines by the machine learning algorithm","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.103100_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/btae342","article-title":"Representations of lipid nanoparticles using large language models for transfection efficiency prediction","volume":"40","author":"Moayedpour","year":"2024","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2026.103100_bib49","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","article-title":"AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery","volume":"15","author":"Xu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103100_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114708","article-title":"Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles","volume":"194","author":"Kumar","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2026.103100_bib51","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib52","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide\u2013protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103100_bib53","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf533","article-title":"Computational toxicology in drug discovery: applications of artificial intelligence in ADMET and toxicity prediction","volume":"26","author":"Zhang","year":"2025","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.xcrm.2026.103100_bib54","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.103100_bib55","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103100_bib56","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103100_bib57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cels.2018.05.014","article-title":"MHCflurry: Open-Source Class I MHC Binding Affinity Prediction","volume":"7","author":"O\u2019Donnell","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.xcrm.2026.103100_bib58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103100_bib59","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103100_bib60","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.103100_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2026.103100_bib62","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3389\/fimmu.2017.01566","article-title":"An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes","volume":"8","author":"Bjerregaard","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103100_bib63","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103100_bib64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41541-025-01258-y","article-title":"AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development","volume":"10","author":"Villanueva-Flores","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.xcrm.2026.103100_bib65","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41467-022-28421-6","article-title":"Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103100_bib66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41698-022-00283-7","article-title":"Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty","volume":"6","author":"Badowski","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.xcrm.2026.103100_bib67","first-page":"9","article-title":"RNA Biomarkers: Frontier of Precision Medicine for Cancer","volume":"3","author":"Xi","year":"2017","journal-title":"Noncoding. RNA"},{"key":"10.1016\/j.xcrm.2026.103100_bib68","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/cancers11081170","article-title":"Noncoding RNAs in Extracellular Fluids as Cancer Biomarkers: The New Frontier of Liquid Biopsies","volume":"11","author":"Pardini","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.103100_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41568-020-00306-0","article-title":"RNA in cancer","volume":"21","author":"Goodall","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.103100_bib70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","article-title":"Targeting non-coding RNAs to overcome cancer therapy resistance","volume":"7","author":"Chen","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.649619","article-title":"Long Non-coding RNAs: Mechanisms, Experimental, and Computational Approaches in Identification, Characterization, and Their Biomarker Potential in Cancer","volume":"12","author":"Chowdhary","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.xcrm.2026.103100_bib72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12967-025-06139-5","article-title":"The clinical application of artificial intelligence in cancer precision treatment","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib73","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","article-title":"Multi-omic machine learning predictor of breast cancer therapy response","volume":"601","author":"Sammut","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103100_bib74","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1016\/j.cell.2024.10.024","article-title":"Small and long non-coding RNAs: Past, present, and future","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103100_bib75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib76","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41746-024-01274-7","article-title":"PRISM: Patient Records Interpretation for Semantic clinical trial Matching system using large language models","volume":"7","author":"Gupta","year":"2024","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib77","doi-asserted-by":"crossref","first-page":"9074","DOI":"10.1038\/s41467-024-53081-z","article-title":"Matching patients to clinical trials with large language models","volume":"15","author":"Jin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103100_bib78","article-title":"End-to-end clinical trial matching with large language models","author":"Ferber","year":"2024","journal-title":"arXiv"},{"key":"10.1016\/j.xcrm.2026.103100_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1021\/acs.jpcc.3c05938","article-title":"Leveraging Machine Learning for Size and Shape Analysis of Nanoparticles: A Shortcut to Electron Microscopy","volume":"128","author":"Glaubitz","year":"2024","journal-title":"J. Phys. Chem. C"},{"key":"10.1016\/j.xcrm.2026.103100_bib80","first-page":"1280","article-title":"Machine learning-guided high throughput nanoparticle design","volume":"3","author":"Ortiz-Perez","year":"2024","journal-title":"Dig. Dis."},{"key":"10.1016\/j.xcrm.2026.103100_bib81","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tibtech.2022.08.007","article-title":"Artificial intelligence and machine learning applications in biopharmaceutical manufacturing","volume":"41","author":"Rathore","year":"2023","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103100_bib82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/acs.oprd.4c00382","article-title":"Overview and Recent Advances in the Purification and Isolation of Therapeutic Oligonucleotides","volume":"29","author":"Abe","year":"2025","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.xcrm.2026.103100_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4015","article-title":"Modern approaches to therapeutic oligonucleotide manufacturing","volume":"384","author":"Obexer","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103100_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1426129","article-title":"Understanding the impact of in vitro transcription byproducts and contaminants","volume":"11","author":"Lenk","year":"2024","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.xcrm.2026.103100_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2024.100996","article-title":"Machine learning-driven optimization of mRNA-lipid nanoparticle vaccine quality with XGBoost\/Bayesian method and ensemble model approaches","volume":"14","author":"Maharjan","year":"2024","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.xcrm.2026.103100_bib86","unstructured":"U.S. Food and Drug Administration, Health Canada, and Medicines and Healthcare products Regulatory Agency (2021). Good Machine Learning Practice for Medical Device Development: Guiding Principles. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/good-machine-learning-practice-medical-device-development-guiding-principles."},{"key":"10.1016\/j.xcrm.2026.103100_bib87","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1056\/NEJMc2104626","article-title":"The Clinician and Dataset Shift in Artificial Intelligence","volume":"385","author":"Finlayson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41746-020-00367-3","article-title":"Second opinion needed: communicating uncertainty in medical machine learning","volume":"4","author":"Kompa","year":"2021","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib89","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41746-020-00323-1","article-title":"The future of digital health with federated learning","volume":"3","author":"Rieke","year":"2020","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib90","article-title":"Federated machine learning in healthcare: A systematic review on clinical applications and technical architecture","volume":"5","author":"Teo","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107441","article-title":"Application of uncertainty quantification to artificial intelligence in healthcare: A review of last decade (2013\u20132023)","volume":"165","author":"Seoni","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.xcrm.2026.103100_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/wics.70046","article-title":"Secure Multiparty Computation for Privacy-Preserving Machine Learning in Healthcare: A Comprehensive Survey","volume":"17","author":"Naresh","year":"2025","journal-title":"WIREs Comput. Stat."},{"key":"10.1016\/j.xcrm.2026.103100_bib93","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114760","article-title":"RNA-based medicine: from molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.xcrm.2026.103100_bib94","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib95","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103100_bib96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/nat.2022.0040","article-title":"Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides","volume":"33","author":"L\u00f8vendorf","year":"2023","journal-title":"Nucleic Acid Therapeut."},{"key":"10.1016\/j.xcrm.2026.103100_bib97","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103100_bib98","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103100_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgad203","article-title":"Identification of small-molecule inhibitors against the interaction of RNA-binding protein PSF and its target RNA for cancer treatment","volume":"2","author":"Takayama","year":"2023","journal-title":"PNAS Nexus"},{"key":"10.1016\/j.xcrm.2026.103100_bib100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.103100_bib101","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/s41388-023-02780-w","article-title":"Going circular: history, present, and future of circRNAs in cancer","volume":"42","author":"Pisignano","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2026.103100_bib102","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41467-018-05096-6","article-title":"Engineering circular RNA for potent and stable translation in eukaryotic cells","volume":"9","author":"Wesselhoeft","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103100_bib103","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302191120","article-title":"Circular RNA vaccine induces potent T cell responses","volume":"120","author":"Amaya","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103100_bib104","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103100_bib105","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.103100_bib106","first-page":"5","article-title":"Advances in Personalized Cancer Vaccine Development: AI Applications from Neoantigen Discovery to mRNA Formulation","volume":"5","author":"Kong","year":"2025","journal-title":"BioChemistry (Rajkot, India)"},{"key":"10.1016\/j.xcrm.2026.103100_bib107","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1126\/science.aaa8415","article-title":"Machine learning: Trends, perspectives, and prospects","volume":"349","author":"Jordan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103100_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/science.adr8470","article-title":"Deep generative models design mRNA sequences with enhanced translational capacity and stability","volume":"390","author":"Zhang","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103100_bib109","first-page":"1","article-title":"Artificial intelligence-guided design of LNPs for in vivo targeted mRNA delivery via analysis of the spatial conformation of ionizable lipids","author":"Su","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.103100_bib117","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib118","first-page":"6","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders. Commun","volume":"4","author":"Lauffer","year":"2024","journal-title":"M\u00e9d. Sur"},{"key":"10.1016\/j.xcrm.2026.103100_bib119","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/genes16121468","article-title":"Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders","volume":"16","author":"Leckie","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.xcrm.2026.103100_bib120","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ymthe.2025.02.045","article-title":"Clinical applications of oligonucleotides for cancer therapy","volume":"33","author":"DeFranciscis","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102256","article-title":"Advancing Cancer Treatments: The role of oligonucleotides-based therapies in driving progress","volume":"35","author":"Dume","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103100_bib122","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103100_bib123","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.xcrm.2026.103100_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102761","article-title":"An LNA gapmer antisense oligonucleotide inhibitor of human NNMT","volume":"36","author":"Chen","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103100_bib125","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-023-06834-7","article-title":"Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides","volume":"625","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103100_bib126","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.103100_bib127","article-title":"Artificial Intelligence and the Evolving Landscape of Immunopeptidomics","volume":"19","author":"Vo","year":"2025","journal-title":"Proteonomics Clin. Appl."},{"key":"10.1016\/j.xcrm.2026.103100_bib110","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1021\/acsmedchemlett.0c00659","article-title":"Risdiplam, the first approved small molecule splicing modifier drug as a blueprint for future transformative medicines","volume":"12","author":"Ratni","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.xcrm.2026.103100_bib111","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S2468-1253(22)00233-3","article-title":"ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension","volume":"7","author":"Vermeire","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103100_bib113","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41598-018-37813-y","article-title":"Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing","volume":"9","author":"Vautrin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.103100_bib114","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000560","article-title":"ABX464 (obefazimod) upregulates miR-124 to reduce proinflammatory markers in inflammatory bowel diseases","volume":"14","author":"Apolit","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.xcrm.2026.103100_bib115","article-title":"miR-124 suppresses growth of human colorectal cancer by inhibiting STAT3","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.103100_bib143","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1039\/D3MD00685A","article-title":"Small molecules modulating RNA splicing: a review of targets and future perspectives","volume":"15","author":"Bouton","year":"2024","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.xcrm.2026.103100_bib144","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/cells12131730","article-title":"Novel small molecules in IBD: current state and future perspectives","volume":"12","author":"Jefremow","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.xcrm.2026.103100_bib128","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2355037","article-title":"Decoding trends in mRNA vaccine research: A comprehensive bibliometric study","volume":"20","author":"Zhang","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.xcrm.2026.103100_bib129","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf263","article-title":"Artificial intelligence-driven circRNA vaccine development: multimodal collaborative optimization and a new paradigm for biomedical applications","volume":"26","author":"Zhao","year":"2025","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.xcrm.2026.103100_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105638","article-title":"Unlocking the potential of circular RNA vaccines: a bioinformatics and computational biology perspective","volume":"114","author":"Liu","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2026.103100_bib131","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ymthe.2025.10.038","article-title":"CircRNA: Unlocking new frontiers in therapeutic and vaccine development","volume":"34","author":"Bahrulolum","year":"2026","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib132","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/pathogens13080692","article-title":"Advances in Engineering Circular RNA Vaccines","volume":"13","author":"Zhang","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.xcrm.2026.103100_bib133","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103100_bib134","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib145","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s40262-024-01409-9","article-title":"Machine learning methods for precision dosing in anticancer drug therapy: a scoping review","volume":"63","author":"Teplytska","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.xcrm.2026.103100_bib146","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/cpt.3356","article-title":"Model-informed reinforcement learning for enabling precision dosing via adaptive dosing","volume":"116","author":"Tosca","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2026.103100_bib116","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/gut.2011.239145","article-title":"The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2","volume":"61","author":"Zheng","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2026.103100_bib135","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2026.103100_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2025.1675209","article-title":"Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives","volume":"16","author":"Makkar","year":"2025","journal-title":"Front. Genet."},{"key":"10.1016\/j.xcrm.2026.103100_bib137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.103100_bib138","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1093\/nar\/gkx135","article-title":"N1-methyl-pseudouridine in mRNA enhances translation through eIF2\u03b1-dependent and independent mechanisms by increasing ribosome density","volume":"45","author":"Svitkin","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.103100_bib139","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1021\/acs.molpharmaceut.5c00474","article-title":"Drug Delivery Systems for Overcoming Physical Barriers in Cancer Therapy","volume":"22","author":"Yi","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.xcrm.2026.103100_bib140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.omtn.2018.11.019","article-title":"The modulatory role of microRNA-873 in the progression of KRAS-driven cancers","volume":"14","author":"Mokhlis","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.103100_bib141","first-page":"2519","article-title":"miR-873 induces lung adenocarcinoma cell proliferation and migration by targeting SRCIN1","volume":"7","author":"Gao","year":"2015","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.xcrm.2026.103100_bib142","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/14760584.2024.2354251","article-title":"Research progress on the quality control of mRNA vaccines","volume":"23","author":"Hu","year":"2024","journal-title":"Expert Rev. Vaccines"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:13:13Z","timestamp":1792509193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":145,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666379126005173"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103100","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AI-integrated RNA therapeutics in precision oncology","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103100"}}